GÖTTINGEN, Germany, March 25,
2022 /PRNewswire/ -- On the occasion of its virtual
Annual General Shareholders' Meeting today, life science company
Sartorius takes a positive look back at the past year and provides
shareholders with details on further growth prospects. "Life
sciences and the biopharmaceutical industry are currently in a very
dynamic and innovative phase. Significant progress is being made at
an increasing pace in the development of advanced therapies, such
as cell and gene therapy methods, and mRNA technology is showing
great potential as well. At the same time, sustainable megatrends
in our target markets are supporting the excellent opportunities
for growth. The global population and the number of elderly people
is growing, and the need for new and effective medicines is growing
along with it," said Executive Board Chairman and CEO Joachim Kreuzburg. "Major challenges in this
respect are the high costs and long timelines that are associated
with the development and manufacturing of new biopharmaceuticals.
With its innovative technologies, Sartorius plays an important role
when it comes to translating new knowledge into effective patient
care more quickly and more cost-effectively."
Fiscal 2021 was extraordinarily positive for Sartorius: Group
sales revenue increased by almost 50 percent in constant currencies
from the previous year, and the underlying EBITDA1
margin jumped by 4.5 percentage points to 34.1 percent. "We
significantly grew in the Lab Products & Services Division as
well as the Bioprocess Solutions Division, with high growth rates
and new record levels in all product segments and in all regions,"
said Kreuzburg. He also addressed the outlook for the current
fiscal year, forecasting Group sales revenue in 2022 to increase by
about 15 percent to 19 percent and an underlying EBITDA margin
reaching the high level of around 34 percent again.
The mid-term targets for 2025, which anticipate sales revenue of
around 5 billion euros and an
underlying EBITDA margin of around 34 percent, were also confirmed.
All forecasts are based on constant currencies.
Kreuzburg confirmed that Sartorius plans to invest between 550
million and 600 million euros in the
current year alone in light of the high demand: "We are continuing
to invest in expanding our capacities worldwide at full speed."
In addition to short- and mid-term growth prospects, Kreuzburg
also addressed the Group's sustainability strategy. "With our focus
on technologies for the rapid and cost-effective development and
manufacture of medicines and vaccines, we are directly addressing
one of the United Nations' Sustainable Development Goals: good
health and well-being for all people," said Kreuzburg. "At the same
time, it is necessary to limit the effects of the business on the
climate by reducing greenhouse gas emissions in the best possible
way. This is why we introduced the reduction of the
CO2 emission intensity as a new performance
indicator for the company's management system at the beginning of
2022." CO2 emission intensity indicates the amount of
greenhouse gas emissions in CO2 equivalents in relation
to sales revenue. Sartorius plans to reduce this figure, which is
particularly meaningful for high-growth companies, by an average of
around 10 percent per year, thus reducing it by around 70 percent
by 2030. For the corresponding comprehensive measures, the company
expects over time additional annual expenses of around 1 percent of
Group sales revenue.
1 Underlying EBITDA: earnings before interest, taxes,
depreciation and amortization and adjusted for extraordinary
items
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language release. Sartorius shall not assume
any liability for the correctness of this translation. The original
German release is the legally binding version.
Additional documents for the Annual General Shareholders'
Meeting 2022
https://www.sartorius.com/en/company/investor-relations/sartorius-ag-investor-relations/shareholders-meeting
Additional links
Annual Report 2021
Current image files
Financial calendar
April 21, 2022 -
Publication of first-quarter figures (January to March
2022)
July 21, 2022 -
Publication of first-half figures (January to June 2022)
October 19, 2022 -
Publication of nine-month figures (January to September 2022)
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2021, the company earned sales revenue of
some 3.45 billion euros. At the end
of 2021, nearly 14,000 people were employed at the Group's
approximately 60 manufacturing and sales sites, serving customers
around the globe.
Follow Sartorius on Twitter @Sartorius_Group and on
LinkedIn.
Contact
Timo Lindemann
Press Relations
+49 (0)551 308 4724
timo.lindemann@sartorius.com
Logo -
https://mma.prnewswire.com/media/1472792/Sartorius_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sartorius-annual-general-shareholders-meeting-focus-on-innovation-growth-and-sustainability-301510743.html
SOURCE Sartorius AG
